Sanofi (SNY) Income towards Parent Company (2009 - 2026)
Sanofi's (SNY) quarterly Income towards Parent Company came in at $398.7 million in Q2 2026, down 91.06% year-over-year from $4.5 billion in Q2 2025, and down 78.9% quarter-over-quarter from $1.9 billion in Q1 2026.
Analysis
Sanofi (SNY) Income towards Parent Company (2009 - 2026) Analysis & Trends
Sanofi has disclosed Income towards Parent Company across 18 years of filings, most recently posting $398.7 million for Q2 2026.
- In Q2 2026, Income towards Parent Company fell 91.06% year-over-year to $398.7 million; the TTM figure through Jun 2026 stood at $4.7 billion (down 53.64% YoY), while the FY2025 annual figure was $9.1 billion, up 51.13% from the prior year.
- Income towards Parent Company came in at $398.7 million for Q2 2026 at Sanofi, down from $1.9 billion in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $10.1 billion in Q3 2025 to a low of -$7.7 billion in Q4 2025.
- Average Income towards Parent Company over 5 years is $1.9 billion, with a median of $1.9 billion recorded in 2025.
- The largest YoY upside for Income towards Parent Company was 272.1% in 2025 against a maximum downside of 1543.62% in 2025.
- Over 5 years, Income towards Parent Company stood at $5.4 billion in 2022, then tumbled by 111.13% to -$597.1 million in 2023, then surged by 189.3% to $533.2 million in 2024, then tumbled by 1543.62% to -$7.7 billion in 2025, then surged by 105.18% to $398.7 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were $398.7 million in Q2 2026, $1.9 billion in Q1 2026, and -$7.7 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 398.69 Mn |
| Mar 31, 2026 | 1.89 Bn |
| Dec 31, 2025 | -7.70 Bn |
| Sep 30, 2025 | 10.07 Bn |
| Jun 30, 2025 | 4.46 Bn |
| Mar 31, 2025 | 1.97 Bn |
| Dec 31, 2024 | 533.23 Mn |
| Sep 30, 2024 | 3.09 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Mar 31, 2024 | 1.23 Bn |
| Dec 31, 2023 | -597.15 Mn |
| Sep 30, 2023 | 2.75 Bn |
| Jun 30, 2023 | 1.56 Bn |
| Mar 31, 2023 | 2.14 Bn |
| Dec 31, 2022 | 5.37 Bn |
| Sep 30, 2022 | 2.09 Bn |
| Jun 30, 2022 | 1.25 Bn |
| Mar 31, 2022 | 2.25 Bn |
| Dec 31, 2021 | 5.80 Bn |
| Sep 30, 2021 | 2.72 Bn |